Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 46.0% in November

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 11,400 shares, a decrease of 46.0% from the October 31st total of 21,100 shares. Currently, 2.1% of the company’s stock are sold short. Based on an average daily volume of 336,800 shares, the days-to-cover ratio is presently 0.0 days.

Bluejay Diagnostics Trading Up 0.6 %

BJDX stock traded up $0.02 during midday trading on Friday, reaching $3.50. The company had a trading volume of 8,284 shares, compared to its average volume of 103,749. The company has a 50 day moving average of $5.18 and a two-hundred day moving average of $54.42. The company has a market capitalization of $1.89 million, a P/E ratio of 0.00 and a beta of 0.73. Bluejay Diagnostics has a 1 year low of $3.03 and a 1 year high of $1,564.00.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. CVI Holdings LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned about 19.69% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.